VBI Vaccines FY 2023 revenue $8.7M, net loss $92.8M; PreHevbrio sales up 234%

VBI Vaccines Inc/BC

2024-Q1 EPS reported -$0.73 revenue$1,214,000

PreHevbrio net revenue $3.1M in 2023, up 234% YoY; Q1 2024 US volume ~65% of FY2023.
VBI-1901 Phase 2b in GBM: 40% disease control (2/5 stable) vs 0% control; more data mid/year-end 2024.
Agreement to sell Rehovot manufacturing to Brii Bio for up to $33M, reducing K2HV debt from $50M to $17M.
Cash $23.7M at Dec 31, 2023 (down from $62.6M); net loss $92.8M ($6.03/share) vs $113.3M in 2022.
R&D expense $9.3M (down 40%), SG&A $42.1M (down 25%) after April 2023 workforce reduction.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

VBI Vaccines Inc/BC reported the year ended December 31, 2023 results: revenue $3.1 million.

Period: the year ended December 31, 2023
Revenue: $3.1 million
Result: reported results

Exact text from the filing

Product revenue, net of $3.1 million in 2023 compared to $0.9 million in 2022, a 234% year-over-year increase

View on SEC.gov

516 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001493152-24-014743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.